These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 16499138

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 3. Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
    Viale PH.
    Clin J Oncol Nurs; 2005 Feb; 9(1):77-84. PubMed ID: 15751501
    [Abstract] [Full Text] [Related]

  • 4. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM.
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting.
    Oo TH, Hesketh PJ.
    Nat Clin Pract Oncol; 2005 Apr; 2(4):196-201. PubMed ID: 16264934
    [Abstract] [Full Text] [Related]

  • 7. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S, 99-04 Palonosetron Study Group.
    Cancer; 2003 Dec 01; 98(11):2473-82. PubMed ID: 14635083
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Emerging treatments in chemotherapy-induced nausea and vomiting.
    Grunberg SM, Slusher B, Rugo HS.
    Clin Adv Hematol Oncol; 2013 Feb 01; 11(2 Suppl 1):1-18; quiz 2 p following 18. PubMed ID: 23598819
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM.
    Expert Opin Drug Metab Toxicol; 2009 Dec 01; 5(12):1577-86. PubMed ID: 19929251
    [Abstract] [Full Text] [Related]

  • 13. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
    Durand JP, Madelaine I, Scotté F.
    Bull Cancer; 2009 Oct 01; 96(10):951-60. PubMed ID: 19734117
    [Abstract] [Full Text] [Related]

  • 14. Update on the management of chemotherapy-induced nausea and vomiting.
    Viale PH.
    J Infus Nurs; 2006 Oct 01; 29(5):283-92. PubMed ID: 17035890
    [Abstract] [Full Text] [Related]

  • 15. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
    Slatkin NE.
    J Support Oncol; 2007 May 01; 5(5 Suppl 3):1-9. PubMed ID: 17566383
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C, Slusher BS.
    Cancer Treat Rev; 2015 Dec 01; 41(10):904-13. PubMed ID: 26442475
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.
    Osorio-Sanchez JA, Karapetis C, Koczwara B.
    Intern Med J; 2007 Apr 01; 37(4):247-50. PubMed ID: 17388865
    [Abstract] [Full Text] [Related]

  • 18. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M, Tsukuda M.
    Expert Opin Pharmacother; 2010 Apr 01; 11(6):1003-14. PubMed ID: 20307224
    [Abstract] [Full Text] [Related]

  • 19. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM, Lenz KL.
    Ann Pharmacother; 2005 Jan 01; 39(1):77-85. PubMed ID: 15562136
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.
    Ann Pharmacother; 2012 Dec 01; 46(12):1637-44. PubMed ID: 23170032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.